Inflammatory Index as a Predictor for Endometrial Cancer: an Observational Study
NCT05657483
Summary
It is a prospective observational trial. Primary goal is identification of an association between alteration of systemic inflammation indices, such as neutrophil-to-lymphocyte ratio (NLR), platelet-t- lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (MRL) and patients risk classification according to European Guidelines. The population is represented by all women being admitted to the Gynecology Ward, through Emergency, who are affected by endometrial cancer. Participants will undergo surgery, and freely express their consent to participate in the study.
Eligibility
Inclusion Criteria: * Patients histologically diagnosed with endometrial cancer. * Patients undergoing surgical staging of the disease. * Patients undergoing full-body CT-scan 30 days before enrollment. * At least 18-year-old patients. Exclusion Criteria: * Unfit to plead. * Patients with chronic inflammatory diseases (IBDs; rheumatic conditions). * Synchronous tumors or cancer diagnosis in the previous 3 years. * Patients undergoing steroid therapy in the last 30 days prior to recruitment
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT05657483